Treatment paradigm for newly diagnosed #AML #EHA22

Ineligibilty for #AML intensive chemotherapy #EHA22

Do you know who runs our journals? Of 959 editors of 93 Hematology journals 74% are men and 87% work in high income countries.

Our contribution to #EHA22 abstract PB2347

Hello Vienna! So excited to be here with Simon Mitchell Dr Eleanor Jayawant Kim Sharp and Emma! #EHA2022 #EHA22 European Hematology Association YoungEHA Sussex Haematology Research Group

Fantastic talk Abdullah Khan presenting our bone marrow organoids model European Hematology Association #EHA22 , Stem cells & Niche session. Great questions from the audience, many of which we are working on for revisions…preliminary paper available on bioRxiv MRC WIMM Kellie Machlus

It wouldn't be right to come to Vienna for the excellent #EHA22 conference without sampling some of the local cuisine...😋

So happy to present my poster at #EHA22 with my mentor Marcio . We have to represent brazil 🇧🇷🇧🇷🇧🇷

The FLT3-ITD allelic ratio is no more 😐

#AML #EHA22

Prof Roddie speaking on dual targeting of CAR-T.
• CD19- escape in approx 1/3 B-Cell malig (ALL / LBCL)
• CD22 less attractive as 2nd target: HLH more common with & activity when used in tanCAR is limited
• CD20 maybe better option
#EHA2022 #lymsm #EHA22

1000s of attendees & I haven’t met any other PAs yet! Feeling extra proud of all the hard work that went into this poster & the fact it was accepted at #EHA22 when I see all of the incredible work around me - what a great opportunity to share my work and to represent PAs!

Took another picture today morning aswell. Was forced to 😉 coz the 'light was better'. And I thought I was the photographer🤣

#EHA22

At Cologne Central Station about to board a night train to Vienna. I am already looking forward to exciting days at #EHA22 ⁦European Hematology Association⁩. Great to be able to join in person and to reunite with many international colleagues!

Such a pleasure to be back in person to #EHA22 . Superb session now with ⁦Amer Zeidan MBBS,MHS ‏عامر زيدان⁩ ⁦Charlie Craddock CBE⁩ ⁦Medscape Oncology⁩ ⁦Medscape Education⁩

Impressive durability of response from early data of CARTITUDE 2 for patients that relapse <12 months from ASCT. 40% progressed through bridging therapy.
#EHA22 #mmsm

Happy day! 🤩

The study that I presented at #EHA22 was accepted for publication!!
#knowledge #infection #hematology

#CLL 13 online
CIT (150 FCR 79 BR) RV 237 GV 229 GIV 231
2nd co-endpt met
GIVe⬆️PFS vs CIT HR 0.32
G-Ven⬆️PFS vs CIT HR 0.42
PFS not diff: RV vs CIT
3Y PFS
91% GIVe
88% GV
81% RV
75% CIT
✅driven by IGHV unmut #CLL
OS similar
⬆️SM in FCR/BR
ven-O⬆️PFS vs FCR/BR in fit pts #EHA22

Happy to share the results of our Phase 1 Clinical Trial with an academic CAR30 to treat R/R cHL and CD30+ T-cell lymphomas #DrBriones #EHA22 s3.eu-central-1.amazonaws.com/m-anage.com.st…

#EHA22 #leusm Erba: most accrual ex-USA bec Mido was approved in US while this study was ongoing. Sig improvement in OS adding Quiz (31.9 v 15.1mo). Survival best in those who recd Quiz and alloHCT in CR1.

UK myeloma doctors all ready to attend the newly diagnosed myeloma session! #EHA22 #mmsm
awechalekar

#EHA22 #EHA2022 DLBCL treatment overview in Educational Session by Graham Collins.